Appendix Cancer

Colon & Rectal Cancer

Gastric Cancer & Stomach

Ovarian Cancer

Peritoneal Mesothelioma

Primary Peritoneal Cancer or Primary Abdominal Cancer

Pseudomyxoma Peritonei

Cytoreductive surgery of cancers involving the lining of the abdominal cavity (peritoneum) with HIPEC is a comprehensive surgical treatment for carefully selected patients with malignancies arising from or confined to the peritoneal cavity.

Over the past 25 years, much progress has been achieved. There is now substantial clinical evidence that HIPEC is the preferred treatment for patients with Pseudomyxoma Peritonei, Mucinous Adenocarcinoma of the Appendix and Mesothelioma. Additionally, peritoneal metastases from Gastric Cancer and Colon Cancer can also be successfully treated in a significant number of patients.

Certain patients with ovarian cancer may also benefit from cytoreductive surgery and Hipec, which is emerging as an important treatment option, since ovarian cancer is confined to the peritoneal cavity in a majority of patients.

Finally, there has been some success treating low grade sarcomas with metastases confined to the peritoneal cavity. Usually these patients are treated to improve their symptoms.

Many of the cancers treated with HIPEC are diseases treated by multiple disciplines in medicine and surgery. It is important that patients discuss HIPEC therapy with their oncologists and surgeon who can guide their therapy appropriately. Sometimes a referral to a Surgical Oncologist or Gynecological Oncologist performing HIPEC is helpful and necessary early at the time of diagnosis. These doctors can help determine if a patient can benefit from HIPEC and then formulate a comprehensive treatment plan.